The concept of “soft” drugs involves the controlled degradation of substances to treat acute conditions that require a rapid onset and temporary action. Recently, researchers at Bayer AG developed a dual factor IIa/Xa inhibitor featuring an ester bond as a soft spot for the clearance of the substance from plasma through ester bond hydrolysis. These esters, based on the molecular structure of diaminopropionic acid, demonstrated a half-life of 0.2-0.3 hours in vivo, supporting the advancement of the optimized molecule (BAY 3389934) to clinical trials. Explore our collection of diaminopropionic acid derivatives to construct your molecules!
Case study
Download SD files
Download PDF file
We offer
Over 100 compounds based on diaminopropionic acid skeleton from stock on 5-10 gram scale.
